Journal
BIOMATERIALS
Volume 35, Issue 24, Pages 6462-6472Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2014.04.023
Keywords
Cisplatin; Nephrotoxicity; Nanoparticles; Breast cancer; Liposome
Funding
- Science and Technology Development Foundation from Pudong New District, Shanghai, People's Republic of China [PKJ2012-Y11]
- Outstanding Young Foundation from Pudong New District, Shanghai, People's Republic of China [PWRq2011-16]
- Shanghai medical key specialty [ZK2012A26]
Ask authors/readers for more resources
A lipid cisplatin conjugate was synthesized for super-molecular assembly with lipids to form a new generation of liposomal cisplatin formulation, lipocisplatin. In vitro, lipocisplatin has higher efficacy in human ovarian cancer A2780 and human breast cancer MCF-7 with the murine breast cancer cell line 4T1 which is currently an established model for stage IV breast cancer as the most sensitive strain. Moreover, lipocisplatin demonstrated a greater MTD value and relatively longer blood circulation as compared to cisplatin. Lipocisplatin preferentially accumulate drugs to the tumor site, resulting in a better tumor inhibition efficacy. Moreover, lipocisplatin exceeds the size cutoff for kidney clearance, hence it bypasses the nephrotoxicity of cisplatin which is a major curse of one of the most efficient anticancer drugs nowadays in clinic. The results here indicated lipocisplatin may be translated into a new generation of liposomal based cisplatin drug in clinic. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available